{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:05:32Z","timestamp":1790975132421,"version":"4.1.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Control of Salmonella enterica serovar typhi (S. typhi), the agent of typhoid fever, continues to be a challenge in many low- and middle-income countries. The major transmission route of S. typhi is fecal-oral, through contaminated food and water; thus, the ultimate measures for typhoid fever prevention and control include the provision of safe water, improved sanitation, and hygiene. Considering the increasing evidence of the global burden of typhoid, particularly among young children, and the long-term horizon for sustained, effective water and sanitation improvements in low-income settings, a growing consensus is to emphasize preventive vaccination. This review provides an overview of the licensed typhoid vaccines and vaccine candidates under development, and the challenges ahead for introduction.<\/jats:p>","DOI":"10.1093\/cid\/ciaa504","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T07:12:36Z","timestamp":1588921956000},"page":"S141-S150","source":"Crossref","is-referenced-by-count":71,"title":["Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead"],"prefix":"10.1093","volume":"71","author":[{"given":"Khalid Ali","family":"Syed","sequence":"first","affiliation":[{"name":"MSD-Wellcome Trust Hilleman Laboratories Pvt Ltd, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Saluja","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeyoun","family":"Cho","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"KEM Hospital Research Center, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Anh","family":"Wartel","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittal","family":"Mogasale","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lynch","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H","family":"Kim","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"2020073002270832800_CIT0001","first-page":"260","article-title":"Clinical pathogenesis of typhoid fever","volume":"2","author":"Raffatellu","year":"2008","journal-title":"J Infect Dev Ctries"},{"key":"2020073002270832800_CIT0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4161\/gmic.18602","article-title":"Typhoid fever: \u201cyou can\u2019t hit what you can\u2019t see.\u201d","volume":"3","author":"Wangdi","year":"2012","journal-title":"Gut Microbes"},{"key":"2020073002270832800_CIT0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(79)91316-3","article-title":"Identification of gallbladder typhoid carriers by a string device","volume":"1","author":"Gilman","year":"1979","journal-title":"Lancet"},{"key":"2020073002270832800_CIT0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12879-016-1351-3","article-title":"Revisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studies","volume":"16","author":"Mogasale","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2020073002270832800_CIT0005","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2020073002270832800_CIT0006","doi-asserted-by":"crossref","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: a meta-regression approach","volume":"11","author":"Antill\u00f3n","year":"2017","journal-title":"PLOS Negl Trop Dis"},{"key":"2020073002270832800_CIT0007","doi-asserted-by":"crossref","first-page":"e1001921","DOI":"10.1371\/journal.pmed.1001921","article-title":"World Health Organization estimates of the global and regional disease burden of 22 foodborne bacterial, protozoal and viral diseases, 2010: a data synthesis","volume":"12","author":"Kirk","year":"2015","journal-title":"PLOS Med"},{"key":"2020073002270832800_CIT0008","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2020073002270832800_CIT0009","doi-asserted-by":"crossref","first-page":"e0004616","DOI":"10.1371\/journal.pntd.0004616","article-title":"The burden of typhoid and paratyphoid in India: systematic review and meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLOS Negl Trop Dis"},{"key":"2020073002270832800_CIT0010","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1016\/S2214-109X(17)30328-5","article-title":"Updated estimates of typhoid fever burden in sub-Saharan Africa","volume":"5","author":"Kim","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020073002270832800_CIT0011","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2214-109X(17)30022-0","article-title":"Incidence of invasive Salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study","volume":"5","author":"Marks","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020073002270832800_CIT0012"},{"key":"2020073002270832800_CIT0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/CMR.00002-15","article-title":"Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections","volume":"28","author":"Crump","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2020073002270832800_CIT0014","doi-asserted-by":"crossref","first-page":"k5322","DOI":"10.1136\/bmj.k5322","article-title":"Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities","volume":"364","author":"Parry","year":"2019","journal-title":"BMJ"},{"key":"2020073002270832800_CIT0015","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/mBio.00105-18","article-title":"Emergence of an extensively drug resistant Salmonella enterica serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins","volume":"9","author":"Klemm","year":"2018","journal-title":"MBio"},{"key":"2020073002270832800_CIT0016","first-page":"1824","article-title":"Determining the best immunization strategy for protecting African children against invasive salmonella disease","volume":"67","author":"Jeon","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020073002270832800_CIT0017","first-page":"49","article-title":"Typhoid vaccines: WHO position paper","volume":"83","author":"World Health Organization","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"key":"2020073002270832800_CIT0018","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0019","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1080\/21645515.2017.1333681","article-title":"A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions","volume":"13","author":"Mogasale","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2020073002270832800_CIT0020","first-page":"CD001261","article-title":"Vaccines","author":"Engels","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2020073002270832800_CIT0021","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/clinids\/11.Supplement_3.S552","article-title":"Progress in vaccines against typhoid fever","volume":"11(Suppl 3)","author":"Levine","year":"1989","journal-title":"Rev Infect Dis"},{"key":"2020073002270832800_CIT0022","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0140-6736(91)91910-M","article-title":"Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine","volume":"338","author":"Simanjuntak","year":"1991","journal-title":"Lancet"},{"key":"2020073002270832800_CIT0023","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/infdis\/145.3.292","article-title":"A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results","volume":"145","author":"Wahdan","year":"1982","journal-title":"J Infect Dis"},{"key":"2020073002270832800_CIT0024","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2020073002270832800_CIT0025","first-page":"957","article-title":"Vaccination against typhoid fever: present status","volume":"72","author":"Ivanoff","year":"1994","journal-title":"Bull World Health Organ"},{"key":"2020073002270832800_CIT0026","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33(Suppl 3)","author":"Date","year":"2015","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0027","first-page":"51","article-title":"Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination","volume":"3","author":"Westerink","year":"2012","journal-title":"Aging Dis"},{"key":"2020073002270832800_CIT0028","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/INF.0b013e31812565bc","article-title":"Revaccination with locally-produced Vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings","volume":"26","author":"Zhou","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2020073002270832800_CIT0029","doi-asserted-by":"crossref","first-page":"C36","DOI":"10.1016\/j.vaccine.2015.04.029","article-title":"Live attenuated vaccines for invasive Salmonella infections","volume":"33(Suppl 3)","author":"Tennant","year":"2015","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1128\/JB.138.1.155-161.1979","article-title":"Regulation of nonspecific acid phosphatase in Salmonella: phoN and phoP genes","volume":"138","author":"Kier","year":"1979","journal-title":"J Bacteriol"},{"key":"2020073002270832800_CIT0031","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1073\/pnas.86.13.5054","article-title":"A two-component regulatory system (phoP\/phoQ) controls Salmonella typhimurium virulence","volume":"86","author":"Miller","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020073002270832800_CIT0032","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/173.6.1408","article-title":"PhoP\/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers","volume":"173","author":"Hohmann","year":"1996","journal-title":"J Infect Dis"},{"key":"2020073002270832800_CIT0033","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.68.3.1196-1201.2000","article-title":"Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers","volume":"68","author":"Tacket","year":"2000","journal-title":"Infect Immun"},{"key":"2020073002270832800_CIT0034","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.vaccine.2005.08.008","article-title":"Evaluation of Salmonella enterica serovar typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers","volume":"24","author":"Kirkpatrick","year":"2006","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0035","doi-asserted-by":"crossref","first-page":"e11778","DOI":"10.1371\/journal.pone.0011778","article-title":"A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children","volume":"5","author":"Tran","year":"2010","journal-title":"PLOS One"},{"key":"2020073002270832800_CIT0036","doi-asserted-by":"crossref","first-page":"e0004926","DOI":"10.1371\/journal.pntd.0004926","article-title":"Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a","volume":"10","author":"Darton","year":"2016","journal-title":"PLOS Negl Trop Dis"},{"key":"2020073002270832800_CIT0037","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clim.2010.11.006","article-title":"Oral priming with Salmonella typhi vaccine strain CVD 909 followed by parenteral boost with the S. typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans","volume":"138","author":"Wahid","year":"2011","journal-title":"Clin Immunol"},{"key":"2020073002270832800_CIT0038","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d - potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0039","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate - a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2020073002270832800_CIT0040","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infect Immun"},{"key":"2020073002270832800_CIT0041","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"2020073002270832800_CIT0042","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1128\/IAI.72.11.6586-6588.2004","article-title":"Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children","volume":"72","author":"Canh","year":"2004","journal-title":"Infect Immun"},{"key":"2020073002270832800_CIT0043","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002270832800_CIT0044","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0045","doi-asserted-by":"crossref","first-page":"e25398","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLOS One"},{"key":"2020073002270832800_CIT0046","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, Phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2020073002270832800_CIT0047"},{"key":"2020073002270832800_CIT0048"},{"key":"2020073002270832800_CIT0049","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/CVI.00266-09","article-title":"Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates","volume":"17","author":"Cui","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"2020073002270832800_CIT0050","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0051","article-title":"Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report","author":"Capeding","year":"2019","journal-title":"Vaccine"},{"key":"2020073002270832800_CIT0052","doi-asserted-by":"crossref","first-page":"e0211784","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomized clinical trial-Phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PLOS One"},{"key":"2020073002270832800_CIT0053"},{"key":"2020073002270832800_CIT0054","first-page":"90","article-title":"Clinical trial of tetanus toxoid conjugated Vi polysaccharide typhoid vaccine in infants and young children","volume":"7","author":"Garg","year":"2014","journal-title":"Biotechnol Int"},{"key":"2020073002270832800_CIT0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: school based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2020073002270832800_CIT0056","article-title":"Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis MJ. Safety and immunogenicity of Salmonella typhi Vi conjugate vaccine (Peda Typh) in children up to five years. Int J Sci Res Publ 2013; 3:1\u20135."},{"key":"2020073002270832800_CIT0057","article-title":"Chinnasami B, Sadasivam K, Vivekanandhan A, Arunachalam P, Pasupathy S. A study on longevity of immune response after vaccination with Salmonella typhi Vi conjugate vaccine (Pedatyph) in children. J Clin Diag Res 2015; 9:Sc01\u20133."},{"key":"2020073002270832800_CIT0058","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled Phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020073002270832800_CIT0059","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella typhi: a randomised controlled, Phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2020073002270832800_CIT0060","year":"2016"},{"key":"2020073002270832800_CIT0061"},{"key":"2020073002270832800_CIT0062","doi-asserted-by":"crossref","first-page":"e64680","DOI":"10.1371\/journal.pone.0064680","article-title":"Sustained protection in mice immunized with fractional doses of Salmonella enteritidis core and O polysaccharide-flagellin glycoconjugates","volume":"8","author":"Simon","year":"2013","journal-title":"PLOS One"},{"key":"2020073002270832800_CIT0063","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1472-4669.2008.00157.x","article-title":"Gram-negative outer membrane vesicles: beyond the cell surface","volume":"6","author":"Mashburn-Warren","year":"2008","journal-title":"Geobiology"},{"key":"2020073002270832800_CIT0064","doi-asserted-by":"crossref","first-page":"E1143","DOI":"10.1073\/pnas.1425005112","article-title":"Conjugate-like immunogens produced as protein capsular matrix vaccines","volume":"112","author":"Thanawastien","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020073002270832800_CIT0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1586\/14760584.2013.825450","article-title":"Increasing rates of Salmonella paratyphi A and the current status of its vaccine development","volume":"12","author":"Sahastrabuddhe","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2020073002270832800_CIT0066","doi-asserted-by":"crossref","first-page":"010401","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"J Glob Health"},{"key":"2020073002270832800_CIT0067","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Global Burden of Disease (GBD) 2017 Typhoid and Paratyphoid Collaborators","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020073002270832800_CIT0068","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1016\/j.vaccine.2017.08.001","article-title":"Typhoid Vaccine Acceleration Consortium (TyVAC)","volume":"35","author":"Meiring","year":"2017","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_2\/S141\/33546463\/ciaa504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_2\/S141\/33546463\/ciaa504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T02:27:37Z","timestamp":1596076057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/Supplement_2\/S141\/5877822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":68,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2020,7,29]]},"published-print":{"date-parts":[[2020,7,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa504","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,15]]},"published":{"date-parts":[[2020,7,29]]}}}